Adults aged 45 to 64 experienced a nearly doubled rate of esophageal cancer and a 50 percent increase in the precancerous condition Barrett’s esophagus between 2012 and 2019, according to a database analysis of roughly five million patients to be presented at Digestive Disease Week® 2022.

Patients with pancreatic ductal adenocarcinoma (PDAC) were six times more likely to have had gallstone disease within the year prior to diagnosis than non-cancer patients, suggesting gallstones could be a warning sign for this aggressive and deadly cancer, according to research to be presented at Digestive Disease Week® (DDW) 2022. PDAC is the most common pancreatic cancer, accounting for more than 90% of cases, and it is often fatal because it tends to be diagnosed in late stages.

Results of a new European Academy of Dermatology and Venereology (EADV) survey presented today <<FRIDAY>> at EADV’s Spring Symposium show that 1.71% of the adult European general population reported having skin cancer, meaning some 7,304,000 Europeans are estimated to have the disease. The findings from the EADV’s Burden of Skin Disease (BOSD) survey of 44,689 adults from 27 countries indicate the need for an “expansion in skin cancer education across Europe to help the population make safer skin choices,” according to leading dermatologists at the organisation

A team led by Fred Hutchinson Cancer Center immunologist Dr. Martin Prlic, staff scientist Dr. Florian Mair and postdoctoral fellow Dr. Jami Erickson published the findings in Nature that identifies a subset of T cells that show up in great numbers in head and neck tumors, but not in similar tissues of the mouth inflamed by common ailments such as gum disease.

A study published by researchers from Mayo Clinic Cancer Center at Mayo Clinic in Florida and Case Western, Cleveland Medical Center, investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor-T cell therapy (CAR-T cell therapy). The study is published in Cancer Discovery.

Research from the University of Michigan Rogel Cancer Center could provide a new approach to treating an aggressive form of breast cancer. A study led by Duxin Sun, Ph.D., found that targeting the immune microenvironment in lymph nodes and tumors simultaneously led to long-term tumor remission in mice models of metastatic triple negative breast cancer.

Researchers led by investigators at Massachusetts General Hospital (MGH) recently created multiple preclinical models of this condition and used them to show that several drugs can be applied to the skin to cause the lesions to regress, and one topical drug also protected against skin cancer.